Gyamfi Maxwell Afari, Wan Yu-Jui Yvonne
Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas 66160, USA.
J Biol Chem. 2009 Apr 3;284(14):9321-30. doi: 10.1074/jbc.M808861200. Epub 2009 Jan 27.
Peroxisome proliferators, such as the lipid-lowering fibrates that function as agonists for peroxisome proliferator-activated receptor alpha (PPARalpha), induce liver tumors in rodents and may produce cholestasis in humans. Considerable attention has focused on peroxisome proliferator-induced hepatocellular carcinoma, a phenomenon not noted in man, whereas limited studies examine fibrates and other therapeutic drugs that induce cholestasis, a common finding in humans. Moreover, the mechanisms by which fibrates induce hepatocyte proliferation and cholestasis are still not fully understood. We have examined the role of hepatocyte retinoid X receptor alpha (RXRalpha), an essential partner of PPARalpha, in modulating WY-14,643-induced hepatocyte proliferation and cholestasis. WY-14,643 treatment induced hepatomegaly in wild type (WT) mice that was also accompanied by induction of the expression of cyclins D1, D3, A2, and B1 and Cdc2 as well as inhibition of Wee 1. Such changes were either absent or greatly reduced in hepatocyte RXRalpha-null mice. Furthermore, neither WY-14,643 treatment nor RXRalpha deficiency affected apoptosis, indicating the importance of PPARalpha/RXRalpha in regulating Wee 1-mediated Cdc2/cyclin B1 expression for cells to enter into mitosis. WY-14,643 treatment also induced cholestasis and liver injury, which is evidenced by induction of alanine aminotransferase, alkaline phosphatase, and hepatic bile acid levels in WT mice. Hepatocyte RXRalpha deficiency protected the mice from WY-14,643-induced liver injury. WY-14,643-mediated induction of the small heterodimer partner, Mrp3, and Cyp3a11 levels was greater in hepatocyte RXRalpha-null than in WT mouse livers suggesting enhanced repression of bile acid synthesis and increased efflux of bile acids into blood for renal excretion as well as hydroxylation of bile acids because of hepatocyte RXRalpha deficiency. These data establish a crucial role of hepatocyte RXRalpha in regulating WY-14,643-mediated cell cycle progression as well as bile acid homeostasis.
过氧化物酶体增殖剂,如作为过氧化物酶体增殖物激活受体α(PPARα)激动剂发挥作用的降脂贝特类药物,可在啮齿动物中诱发肝肿瘤,并可能在人类中导致胆汁淤积。相当多的注意力集中在过氧化物酶体增殖剂诱导的肝细胞癌上,这是一种在人类中未观察到的现象,而对诱导胆汁淤积(人类常见的发现)的贝特类药物和其他治疗药物的研究有限。此外,贝特类药物诱导肝细胞增殖和胆汁淤积的机制仍未完全了解。我们研究了肝细胞视黄酸X受体α(RXRα)(PPARα的重要伴侣)在调节WY - 14,643诱导的肝细胞增殖和胆汁淤积中的作用。WY - 14,643处理在野生型(WT)小鼠中诱导肝肿大,同时还伴随着细胞周期蛋白D1、D3、A2和B1以及Cdc2表达的诱导以及Wee 1的抑制。在肝细胞RXRα基因敲除小鼠中,这些变化要么不存在,要么大大减少。此外,WY - 14,643处理和RXRα缺乏均不影响细胞凋亡,表明PPARα/RXRα在调节Wee 1介导的Cdc2/细胞周期蛋白B1表达以使细胞进入有丝分裂中具有重要作用。WY - 14,643处理还诱导胆汁淤积和肝损伤,WT小鼠中丙氨酸转氨酶、碱性磷酸酶和肝胆汁酸水平的升高证明了这一点。肝细胞RXRα缺乏可保护小鼠免受WY - 14,643诱导的肝损伤。与WT小鼠肝脏相比,WY - 14,643介导的小异二聚体伴侣、Mrp3和Cyp3a11水平的诱导在肝细胞RXRα基因敲除小鼠肝脏中更大,这表明由于肝细胞RXRα缺乏,胆汁酸合成的抑制增强,胆汁酸向血液中的流出增加以进行肾脏排泄以及胆汁酸的羟基化。这些数据确立了肝细胞RXRα在调节WY - 14,643介导的细胞周期进程以及胆汁酸稳态中的关键作用。